Spatial and Functional Heterogeneities Shape Collective Behavior of Tumor-Immune Networks

PLoS Computational Biology

Volumn 11, Issue 4, 2015, Pages

  Wells, Daniel K ^a,b   Chuang, Yishan ^a   Knapp, Louis M ^a   Brockmann, Dirk ^a,b,c,d   Kath, William L ^a,b,c   Leonard, Joshua N ^a,b,c  

^a Northwestern University   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CELLS; CELL ENGINEERING; CELL SIGNALING; CELLS; CYTOLOGY; DIAGNOSIS; SENSITIVITY ANALYSIS;

CANCER CELLS; COLLECTIVE BEHAVIOUR; CONDITION; FUNCTIONAL HETEROGENEITY; HOST CELLS; IMMUNE NETWORK; SPATIAL HETEROGENEITY; TUMOR GROWTH; TUMOR PROMOTION; TUMOR SUPPRESSION;

TUMORS;

ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL ENGINEERING; CELL HETEROGENEITY; COMPUTER MODEL; DISEASE ASSOCIATION; IMMUNE DEFICIENCY; MATHEMATICAL MODEL; METASTASIS POTENTIAL; NEOPLASM; PROCESS DEVELOPMENT; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL DESTRUCTION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; ALGORITHM; BIOLOGICAL MODEL; BIOLOGICAL THERAPY; BIOLOGY; COMPUTER SIMULATION; HUMAN; IMMUNOLOGY; MACROPHAGE; NEOPLASMS; PATHOLOGY;

CYTOKINE;

ALGORITHMS; CELL- AND TISSUE-BASED THERAPY; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; CYTOKINES; HUMANS; MACROPHAGES; MODELS, IMMUNOLOGICAL; NEOPLASMS;

EID: 84929484411     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004181     Document Type: Article

References (70)

1. Hanahan D, Coussens LM, (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21: 309–322. doi: 10.1016/j.ccr.2012.02.022 22439926
2. Whiteside TL, (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27: 5904–5912. doi: 10.1038/onc.2008.271 18836471
3. Weinberg R, Hanahan D, (1999) The hallmarks of cancer. Cell 100: 57–70.
4. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646–674. doi: 10.1016/j.cell.2011.02.013 21376230
5. Shiao SL, Ganesan AP, Rugo HS, Coussens LM (2011) Immune microenvironments in solid tumors: new targets for therapy. Gene Dev. pp. 2559–2572.
6. Meads MB, Gatenby RA, Dalton WS, (2009) Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 9: 665–674. doi: 10.1038/nrc2714 19693095
7. Tredan O, Galmarini CM, Patel K, Tannock IF, (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99: 1441–1454. 17895480
8. Joyce JA, Pollard JW, (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239–252. doi: 10.1038/nrc2618 19279573
9. Lorusso G, Ruegg C, (2008) The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 130: 1091–1103. doi: 10.1007/s00418-008-0530-8 18987874
10. Lunt SJ, Chaudary N, Hill RP, (2009) The tumor microenvironment and metastatic disease. Clin Exp Metastasis 26: 19–34. doi: 10.1007/s10585-008-9182-2 18543068
11. Spano D, Zollo M, (2012) Tumor microenvironment: a main actor in the metastasis process. Clin Exp Metastasis 29: 381–395. doi: 10.1007/s10585-012-9457-5 22322279
12. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD, (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991–998. 12407406
13. Sica A, Larghi P, Mancino A, Rubino L, Porta C, et al. (2008) Macrophage polarization in tumour progression. Semin Cancer Biol 18: 349–355. doi: 10.1016/j.semcancer.2008.03.004 18467122
14. Allavena P, Sica A, Solinas G, Porta C, Mantovani A, (2008) The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66: 1–9. 17913510
15. Rabinovich GA, Gabrilovich D, Sotomayor EM, (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267–296. 17134371
16. Gajewski TF, Meng Y, Harlin H, (2006) Immune suppression in the tumor microenvironment. J Immunother 29: 233–240. 16699366
17. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, et al. (2006) Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213: 131–145. 16972901
18. Ruffell B, Affara NI, Coussens LM, (2012) Differential macrophage programming in the tumor microenvironment. Trends Immunol 33: 119–126. doi: 10.1016/j.it.2011.12.001 22277903
19. Mantovani A, Sica A, (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22: 231–237. doi: 10.1016/j.coi.2010.01.009 20144856
20. Condeelis J, Pollard JW, (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124: 263–266. 16439202
21. Mosser DM, Edwards JP, (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958–969. doi: 10.1038/nri2448 19029990
22. Qian BZ, Pollard JW, (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39–51. doi: 10.1016/j.cell.2010.03.014 20371344
23. Sica A, Mantovani A, (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122: 787–795. doi: 10.1172/JCI59643 22378047
24. Pollard JW, (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71–78. 14708027
25. Junttila MR, de Sauvage FJ, (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501: 346–354. doi: 10.1038/nature12626 24048067
26. Mao Q, Zhang Y, Fu X, Xue J, Guo W, et al. (2013) A tumor hypoxic niche protects human colon cancer stem cells from chemotherapy. J Cancer Res Clin Oncol 139: 211–222. doi: 10.1007/s00432-012-1310-3 23052691
27. Roussos ET, Condeelis JS, Patsialou A, (2011) Chemotaxis in cancer. Nat Rev Cancer 11: 573–587. doi: 10.1038/nrc3078 21779009
28. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960–1964. 17008531
29. Angell H, Galon J, (2013) From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 25: 261–267. doi: 10.1016/j.coi.2013.03.004 23579076
30. Fridman WH, Pages F, Sautes-Fridman C, Galon J, (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12: 298–306. doi: 10.1038/nrc3245 22419253
31. Deisboeck TS, Zhang L, Yoon J, Costa J, (2009) In silico cancer modeling: is it ready for prime time? Nat Clin Pract Oncol 6: 34–42. doi: 10.1038/ncponc1237 18852721
32. Anderson ARA, Chaplain MAJ, Newman EL, Steele RJC, Thompson AM, (2000) Mathematical Modelling of Tumour Invasion and Metastasis. Journal of Theoretical Medicine 2: 129–154.
33. Deisboeck TS, Wang Z, Macklin P, Cristini V, (2011) Multiscale cancer modeling. Annu Rev Biomed Eng 13: 127–155. doi: 10.1146/annurev-bioeng-071910-124729 21529163
34. Anderson AR, Weaver AM, Cummings PT, Quaranta V, (2006) Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 127: 905–915. 17129778
35. Scott JG, Basanta D, Anderson ARA, Gerlee P, (2013) A mathematical model of tumour self-seeding reveals secondary metastatic deposits as drivers of primary tumour growth. J R Soc Interface 10: 20130011. doi: 10.1098/rsif.2013.0011 23427099
36. Scott JG, Hjelmeland AB, Chinnaiyan P, Anderson AR, Basanta D, (2014) Microenvironmental variables must influence intrinsic phenotypic parameters of cancer stem cells to affect tumourigenicity. PLoS Comput Biol 10: e1003433. doi: 10.1371/journal.pcbi.1003433 24453958
37. Deisboeck TS, (2009) Personalizing medicine: a systems biology perspective. Mol Syst Biol 5: 249. doi: 10.1038/msb.2009.8 19293829
38. Macklin P, Edgerton ME, Thompson AM, Cristini V, (2012) Patient-calibrated agent-based modelling of ductal carcinoma in situ (DCIS): from microscopic measurements to macroscopic predictions of clinical progression. J Theor Biol 301: 122–140. doi: 10.1016/j.jtbi.2012.02.002 22342935
39. Arkin AP, (2013) A wise consistency: engineering biology for conformity, reliability, predictability. Curr Opin Chem Biol 17: 893–901. doi: 10.1016/j.cbpa.2013.09.012 24268562
40. Fischbach MA, Bluestone JA, Lim WA, (2013) Cell-based therapeutics: the next pillar of medicine. Sci Transl Med 5: 179ps177. doi: 10.1126/scitranslmed.3005568 23552369
41. Vonderheide RH, June CH, (2014) Engineering T cells for cancer: our synthetic future. Immunol Rev 257: 7–13. doi: 10.1111/imr.12143 24329786
42. Biswas SK, Sica A, Lewis CE, (2008) Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 180: 2011–2017. 18250403
43. Bingle L, Brown NJ, Lewis CE, (2002) The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196: 254–265. 11857487
44. Gimbrone MA, Jr.Leapman SB, Cotran RS, Folkman J, (1972) Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136: 261–276. 5043412
45. Rejniak KA, (2005) A single-cell approach in modeling the dynamics of tumor microregions. Math Biosci Eng 2: 643–655. 20369945
46. Ravasi T, Wells C, Forest A, Underhill DM, Wainwright BJ, et al. (2002) Generation of diversity in the innate immune system: macrophage heterogeneity arises from gene-autonomous transcriptional probability of individual inducible genes. J Immunol 168: 44–50. 11751944
47. Sung MH, Li N, Lao Q, Gottschalk RA, Hager GL, et al. (2014) Switching of the relative dominance between feedback mechanisms in lipopolysaccharide-induced NF-kappaB signaling. Sci Signal 7: ra6. doi: 10.1126/scisignal.2004764 24425788
48. Watkins SK, Egilmez NK, Suttles J, Stout RD, (2007) IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol 178: 1357–1362. 17237382
49. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, et al. (2005) Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 175: 342–349. 15972667
50. Aldridge BB, Burke JM, Lauffenburger DA, Sorger PK, (2006) Physicochemical modelling of cell signalling pathways. Nat Cell Biol 8: 1195–1203. 17060902
51. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, et al. (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368: 1509–1518. doi: 10.1056/NEJMoa1215134 23527958
52. Rossger K, Charpin-El-Hamri G, Fussenegger M, (2013) A closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice. Nat Commun 4: 2825. doi: 10.1038/ncomms3825 24281397
53. Lemon KP, Armitage GC, Relman DA, Fischbach MA, (2012) Microbiota-targeted therapies: an ecological perspective. Sci Transl Med 4: 137rv135.
54. Burke B, (2003) Macrophages as novel cellular vehicles for gene therapy. Expert Opin Biol Ther 3: 919–924. 12943451
55. Okasora T, Jo JI, Tabata Y, (2008) Augmented anti-tumor therapy through natural targetability of macrophages genetically engineered by NK4 plasmid DNA. Gene Ther 15: 524–530. doi: 10.1038/gt.2008.5 18239606
56. Owen MR, Stamper IJ, Muthana M, Richardson GW, Dobson J, et al. (2011) Mathematical modeling predicts synergistic antitumor effects of combining a macrophage-based, hypoxia-targeted gene therapy with chemotherapy. Cancer Res 71: 2826–2837. doi: 10.1158/0008-5472.CAN-10-2834 21363914
57. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, et al. (2013) CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 19: 1264–1272. doi: 10.1038/nm.3337 24056773
58. Basanta D, Strand DW, Lukner RB, Franco OE, Cliffel DE, et al. (2009) The role of transforming growth factor-beta-mediated tumor-stroma interactions in prostate cancer progression: an integrative approach. Cancer Res 69: 7111–7120. doi: 10.1158/0008-5472.CAN-08-3957 19706777
59. Jiao Y, Torquato S, (2011) Emergent behaviors from a cellular automaton model for invasive tumor growth in heterogeneous microenvironments. PLoS Comput Biol 7: e1002314. doi: 10.1371/journal.pcbi.1002314 22215996
60. Vaupel P, (2004) Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14: 198–206. 15254862
61. Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, et al. (2014) Macrophage IL-10 Blocks CD8(+) T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells. Cancer Cell 26: 623–637. doi: 10.1016/j.ccell.2014.09.006 25446896
62. Zuckerman NS, Yu H, Simons DL, Bhattacharya N, Carcamo-Cavazos V, et al. (2013) Altered local and systemic immune profiles underlie lymph node metastasis in breast cancer patients. Int J Cancer 132: 2537–2547. doi: 10.1002/ijc.27933 23136075
63. Bugelski PJ, Volk A, Walker MR, Krayer JH, Martin P, et al. (2010) Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia. Int J Toxicol 29: 435–466. doi: 10.1177/1091581810374654 20884856
64. Angermann BR, Klauschen F, Garcia AD, Prustel T, Zhang F, et al. (2012) Computational modeling of cellular signaling processes embedded into dynamic spatial contexts. Nat Methods 9: 283–289. doi: 10.1038/nmeth.1861 22286385
65. Halling-Brown M, Pappalardo F, Rapin N, Zhang P, Alemani D, et al. (2010) ImmunoGrid: towards agent-based simulations of the human immune system at a natural scale. Philos Trans A Math Phys Eng Sci 368: 2799–2815. doi: 10.1098/rsta.2010.0067 20439274
66. Narang V, Decraene J, Wong SY, Aiswarya BS, Wasem AR, et al. (2012) Systems immunology: a survey of modeling formalisms, applications and simulation tools. Immunol Res 53: 251–265. doi: 10.1007/s12026-012-8305-7 22528121
67. Han Q, Bagheri N, Bradshaw EM, Hafler DA, Lauffenburger DA, et al. (2012) Polyfunctional responses by human T cells result from sequential release of cytokines. Proc Natl Acad Sci U S A 109: 1607–1612. doi: 10.1073/pnas.1117194109 22160692
68. Chen YY, Smolke CD, (2011) From DNA to targeted therapeutics: bringing synthetic biology to the clinic. Sci Transl Med 3: 106ps142.
69. Ruder WC, Lu T, Collins JJ, (2011) Synthetic biology moving into the clinic. Science 333: 1248–1252. doi: 10.1126/science.1206843 21885773
70. Fritz BR, Timmerman LE, Daringer NM, Leonard JN, Jewett MC, (2010) Biology by design: from top to bottom and back. J Biomed Biotechnol 2010: 232016. doi: 10.1155/2010/232016 21052559